Pharmaceutical News

RSS

Oral chicken interferon-alpha may significantly reduce influenza infection

Avian influenza virus is a threat to the commercial chicken industry and, with its recent rapid spread across China, has also shown the ability for transmission from chickens to humans and other mammals.

29 Jul 2011

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine).

28 Jul 2011

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON™ (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes.

28 Jul 2011

All Canadian provinces except Quebec announce funding agreement for PNH drug, Soliris

L'Association Québécoise de l'HPN regrets that Quebec remains one of the only jurisdictions in the developed world to decline including the only effective life-saving treatment against an ultra-rare blood disease - paroxysmal nocturnal hemoglobinuria (PNH) - on its public drug insurance plan drugs list.

28 Jul 2011

Solazyme launches anti-aging skincare line, Algenist at Space NK stores

Solazyme, Inc., a renewable oil and bioproducts company, has signed a distribution agreement with the United Kingdom's most innovative beauty retailer, Space NK, to expand the sales network of the company's luxury skincare line, Algenist, to include all 60 Space NK stores throughout the country.

28 Jul 2011

Natural recycling system, PPAR agonists can help protect children with heart defects

Children born with heart defects that pummel their lungs with up to three times the normal blood volume quickly find their lungs in jeopardy as well.

28 Jul 2011

Pharmaceutical companies' profit protection hurts global AIDS fight

In her latest piece on the New York Times' "Opinionator" blog, author and journalist Tina Rosenberg argues that the terms of Gilead's recent agreement with the Medicines Patent Pool is "confirmation of a dangerous new trend: middle-income countries as a target market for drug makers."

28 Jul 2011

Smokers are misinformed about safety and efficacy of nicotine replacement therapy

Nearly half of all smokers in the United States attempt to quit at least once per year, yet the majority of these efforts fail. One factor contributing to the low annual rate of successful cessation is that the majority of quit attempts are made without evidence-based treatment such as nicotine replacement therapy.

28 Jul 2011

Dr. Reddy's, FUJIFILM sign MoU to enter partnership in the generic drugs business

FUJIFILM Corporation President and CEO, Shigetaka Komori and Dr. Reddy's Laboratories Ltd. Vice-Chairman and CEO, G V Prasad today signed a Memorandum of Understanding to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan.

28 Jul 2011

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. today announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.

28 Jul 2011

Watson to acquire portfolio of divested generic pharmaceutical products

Watson Pharmaceuticals, Inc. today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the merger between Perrigo Company and Paddock Laboratories.

28 Jul 2011

Britain’s prescription drug use statistics revealed

According to latest NHS figures number of prescriptions dispensed has soared by 70 per cent over the last decade. Every man, woman and child in the country received on average 17.8 prescription items in 2010. The vast majority went to those aged over 60, who received 42.4 items each in 2007.

27 Jul 2011

FDA accepts peginesatide NDA for anemia associated with CKD

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

27 Jul 2011

Cocaine-free topical anaesthetics can effectively treat pain caused by torn skin

While some pain killers need to be injected into the damaged tissue in order to work, topical anaesthetics only need to be spread on the surface. The earliest examples of "topical" anaesthetics contained cocaine, but now a new systematic review has shown that newer agents that don't contain cocaine can effectively treat pain caused by torn skin.

27 Jul 2011

Surge of generics will trigger drop in drug prices

In the next 14 months, seven of the world's 20 best-selling drugs are scheduled to go "off patent." As they do, the brand-name drugs will lose out to generic versions, cutting costs for patients and companies that provide health benefits.

27 Jul 2011

Merck secures worldwide rights to vernakalant i.v.

Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.

27 Jul 2011

Nano-emulsion shows promise for Viagra patch

Sildenafil citrate, commonly known as Viagra, is currently the first choice drug for erectile dysfunction but despite its success oral delivery of the drug is hampered by numerous side effects, the long delay before it starts working and the short amount of time it lasts. Researchers in Egypt think they may have a solution via nanotechnology.

27 Jul 2011

Pharmaceutical News

Oral chicken interferon-alpha may significantly reduce influenza infection

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

All Canadian provinces except Quebec announce funding agreement for PNH drug, Soliris

Solazyme launches anti-aging skincare line, Algenist at Space NK stores

Natural recycling system, PPAR agonists can help protect children with heart defects

Pharmaceutical companies' profit protection hurts global AIDS fight

Smokers are misinformed about safety and efficacy of nicotine replacement therapy

Dr. Reddy's, FUJIFILM sign MoU to enter partnership in the generic drugs business

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

Watson to acquire portfolio of divested generic pharmaceutical products

Britain’s prescription drug use statistics revealed

FDA accepts peginesatide NDA for anemia associated with CKD

Cocaine-free topical anaesthetics can effectively treat pain caused by torn skin

Surge of generics will trigger drop in drug prices

Merck secures worldwide rights to vernakalant i.v.

Nano-emulsion shows promise for Viagra patch

Follow-up dose recommended to defend children against pandemic virus outbreaks

EMA accepts to evaluate Vanda's MAA for oral iloperidone tablets

High-dose vitamin D reduces musculoskeletal pain in breast cancer patients

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News